250 related articles for article (PubMed ID: 8935194)
1. Bladder catheterization and a plasma prostate-specific antigen in patients with benign prostatic hyperplasia and complete urine retention.
Dutkiewicz S; Stepień K; Witeska A
Mater Med Pol; 1995; 27(2):71-3. PubMed ID: 8935194
[TBL] [Abstract][Full Text] [Related]
2. [The effect of acute urinary retention on serum prostate specific antigen concentration].
Hua LX; Wu HF; Sui YG; Cheng SG; Xu ZQ
Zhonghua Nan Ke Xue; 2002; 8(2):134-5. PubMed ID: 12479031
[TBL] [Abstract][Full Text] [Related]
3. Significance of histological prostatitis in patients with urinary retention and underlying benign prostatic hyperplasia or adenocarcinoma of the prostate.
van Vuuren SP; Heyns CF; Zarrabi AD
BJU Int; 2012 Apr; 109(8):1194-7. PubMed ID: 21851551
[TBL] [Abstract][Full Text] [Related]
4. Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms.
Laniado ME; Ockrim JL; Marronaro A; Tubaro A; Carter SS
BJU Int; 2004 Dec; 94(9):1283-6. PubMed ID: 15610106
[TBL] [Abstract][Full Text] [Related]
5. Prognostic role of prostate-specific antigen and prostate volume for the risk of invasive therapy in patients with benign prostatic hyperplasia initially managed with alpha1-blockers and watchful waiting.
Mochtar CA; Kiemeney LA; Laguna MP; van Riemsdijk MM; Barnett GS; Debruyne FM; de la Rosette JJ
Urology; 2005 Feb; 65(2):300-5. PubMed ID: 15708042
[TBL] [Abstract][Full Text] [Related]
6. [Serum PSA and transition zone index as predictors of acute urinary retention in benign prostate hyperplasia].
Zhu S; Chen S; Li Q; Lin Z; Zheng S; Weng M
Zhonghua Nan Ke Xue; 2004 Jan; 10(1):24-5. PubMed ID: 14979202
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
[TBL] [Abstract][Full Text] [Related]
8. Effect of transurethral indwelling catheter on serum prostate-specific antigen level in benign prostatic hyperplasia.
Batislam E; Arik AI; Karakoc A; Uygur MC; Germiyanoğlu RC; Erol D
Urology; 1997 Jan; 49(1):50-4. PubMed ID: 9000185
[TBL] [Abstract][Full Text] [Related]
9. Prostate biopsy in patients with long-term use of indwelling bladder catheter: what is the rationale?
Antunes AA; Barbosa JA; Reis ST; Guariero MS; Fukushima JT; Dall'oglio MF; Freire Gde C; Lucon AM; Leite KR; Srougi M
Urol Oncol; 2012 Sep; 30(5):620-3. PubMed ID: 20933446
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of histological prostatitis in men with benign prostatic hyperplasia or adenocarcinoma of the prostate presenting without urinary retention.
Edlin RS; Heyns CF; Van Vuuren SP; Zarrabi AD
S Afr J Surg; 2012 Nov; 50(4):127-30. PubMed ID: 23217554
[TBL] [Abstract][Full Text] [Related]
11. [Serum and urine prostate-specific antigen ratio: its value in the distinction between prostate cancer and adenoma when serum prostate-specific antigen level is between 4 and 10 ng/ml].
Irani J; Millet C; Levillain P; Doré B; Bégon F; Aubert J
Chirurgie; 1997; 122(8-9):478-82. PubMed ID: 9616891
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
Ho PJ; Baxter RC
Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
[TBL] [Abstract][Full Text] [Related]
13. [Changes in the levels of prostate-specific antigen and its molecular forms with alpha 1-antichymotrypsin in patients with benign prostatic hyperplasia].
Grigor'ev ME; Mazo EB; Chekhonin VP
Urol Nefrol (Mosk); 1998; (4):33-7. PubMed ID: 9727319
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
[TBL] [Abstract][Full Text] [Related]
15. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.
Ramos CG; Carvahal GF; Mager DE; Haberer B; Catalona WJ
J Urol; 1999 Nov; 162(5):1587-90. PubMed ID: 10524873
[TBL] [Abstract][Full Text] [Related]
16. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
[TBL] [Abstract][Full Text] [Related]
17. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
18. [Rebound of prostate specific antigen after discontinuation of antiandrogen therapy for benign prostatic hyperplasia].
Noguchi K; Uemura H; Takeda M; Sekiguchi Y; Ogawa K; Hosaka M
Hinyokika Kiyo; 2000 Sep; 46(9):605-7. PubMed ID: 11107528
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
20. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate.
Volkan T; Ihsan TA; Yilmaz O; Emin O; Selcuk S; Koray K; Bedi O
Eur Urol; 2005 Oct; 48(4):608-13. PubMed ID: 16135396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
